Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?
Oktávia Tarjányi1, Katalin Olasz2, Fanni Rátky1
1Department of Medical Biology, Medical School, University of Pecs, H-7624 Pecs, Hungary.
Abstract:
Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to the destruction of peripheral joint cartilage and bone tissue. Despite the advent of biological therapies in the past decades, the complete remission of RA patients is still out of reach. Therefore, the search for novel therapeutic approaches is still open in the field of RA. Proteasome inhibitors (PIs) were originally designed to be used in hematological malignancies like multiple myeloma. However, evidence has shown that they are potent inhibitors of the NF-κB pathway, which plays a pivotal role in inflammatory processes and RA. Furthermore, inhibition of cell activation and induction of apoptosis was also reported about PIs. In the present review, we summarize the current knowledge about the potential effects of PIs in RA based on reports from animal and human studies. We believe that there is substantial potential in the use of PIs in RA therapy either alone or in combination with the medications already used.
Insights
Proteasome inhibitors show promise for treating rheumatoid arthritis (RA), a chronic autoimmune disease. These agents may offer new therapeutic options for RA patients, potentially improving outcomes when used alone or with existing treatments.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune condition causing joint destruction.
- Current biological therapies offer limited complete remission for RA patients.
- Novel therapeutic strategies for RA are actively being investigated.
Purpose of the Study:
- To review the potential therapeutic effects of proteasome inhibitors (PIs) in rheumatoid arthritis.
- To summarize existing evidence from animal and human studies on PIs for RA.
- To explore PIs as a novel treatment avenue for RA.
Main Methods:
- Literature review of studies on proteasome inhibitors and rheumatoid arthritis.
- Analysis of data from animal models of RA.
- Examination of human clinical data regarding PI efficacy and safety in RA.
Main Results:
- Proteasome inhibitors target the NF-κB pathway, crucial in RA inflammation.
- PIs have demonstrated inhibition of cell activation and induction of apoptosis in relevant models.
- Evidence suggests PIs possess anti-inflammatory and joint-protective properties in RA contexts.
Conclusions:
- Proteasome inhibitors hold significant potential for RA therapy.
- PIs may be effective as monotherapy or in combination with current RA medications.
- Further research into PIs could lead to improved management of rheumatoid arthritis.
Related Concept Videos
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF